# A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

> **NCT00816686** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 7 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Kidney Neoplasms
- Kidney Diseases

## Interventions

- **BIOLOGICAL:** AGS-16M18

## Key facts

- **NCT ID:** NCT00816686
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Trial was terminated due to the need to re-formulate the study drug.
- **Last updated:** 2013-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00816686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00816686, "A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00816686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*